ST Pharm projected Q2 earnings beat expectations on oligonucleotide sales

ST Pharm (에스티팜) is expected to record second‑quarter results that exceed market expectations, supported by the commercial shipment of its oligonucleotide medicines and new order intake. Hana Securities forecast on the 13th that the company will achieve consolidated revenue of 103.4 billion KRW and operating profit of 20.8 billion KRW for Q2, representing year‑over‑year increases of 51.5% and 60.8% respectively, and beating consensus estimates by 3.2% and 14.9%. The improvement is attributed primarily to the oligonucleotide business. Analysts anticipate that the second half of the year will sustain growth, with upcoming HIV treatment trial results and additional orders serving as key catalysts.